RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
RenovoRx, Inc.NASDAQ: RNXT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $1.23M fell 25.2% year over year, behind the -8.9% change in trailing-twelve-month research & development. Sequentially, it fell 18.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- Research & development amounted to 558.2% of revenue in FY2025, down 13453.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -8.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.27M USD
- Year-over-year change
- +4.0%
- 4-year CAGR
- +19.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.27M | +4.0% |
| FY2024 | 2024-12-31 | 6.03M | +6.3% |
| FY2023 | 2023-12-31 | 5.67M | +31.8% |
| FY2022 | 2022-12-31 | 4.3M | +41.5% |
| FY2021 | 2021-12-31 | 3.04M | — |
Research & Development vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 research & development of $5.84M is the lowest of the 6 companies compared; the peer median is $15.03M.
- Its year-over-year change of -8.9% is the 4th highest of 6, against a peer median of -1.8%.
- Research & development amounts to 392.2% of revenue for RNXT, versus a peer median of 56.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $23.45M | -1.8% | -5.3% | — | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $14.87M | +36.6% | +1076.5% | — | |
| LTM Mar 2026 | $9.98M | -34.1% | +10.2% | — | |
| LTM Mar 2026 | $5.84M | -8.9% | +13.4% | 392.2% | |
| Peer median (excluding RNXT) | $15.03M | -1.8% | +10.2% | 56.6% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 43K | 1.12M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 327K |
| Gross Profit | 0 | 0 | 0 | 43K | 796K |
| Gross Margin | — | — | — | 100.0% | 70.9% |
| Research & Development | 3.04M | 4.3M | 5.67M | 6.03M | 6.27M |
| Selling, General & Admin | 2.63M | 5.65M | 5.73M | 4.99M | 7.04M |
| Operating Expenses | 5.67M | 9.95M | 11.4M | 11.01M | 13.31M |
| Depreciation & Amortization | 9K | 6K | 6K | 0 | 2K |
| EBITDA | (5.48M) | (9.83M) | (10.12M) | (8.81M) | (11.17M) |
| EBITDA Margin | — | — | — | -20497.7% | -994.3% |
| Operating Income | (5.67M) | (9.95M) | (11.4M) | (10.97M) | (12.51M) |
| Operating Margin | — | — | — | -25511.6% | -1114.0% |
| Interest Income | 70K | 57K | 0 | 384K | 427K |
| Interest Expense | 904K | 57K | 108K | 0 | 0 |
| Other Income / Expenses | (653K) | 61K | 1.16M | 2.16M | 1.34M |
| Income Before Tax | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Pre-Tax Margin | — | — | — | -20497.7% | -994.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Net Margin | — | — | — | -20497.7% | -994.5% |
| EPS (Basic) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| EPS (Diluted) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| Weighted Avg Shares | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
| Weighted Avg Shares (Diluted) | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.